The Egyptian Drug Authority (EDA) has updated its regulatory framework for the import and customs clearance of pharmaceutical products, raw materials, and packaging supplies. The revised guidance introduces enhanced import authorization requirements, stricter GMP and quality compliance expectations, and new supplier and broker validation measures. It also includes digital system integration, stronger import controls, and more detailed customs clearance procedures. Additional updates cover Risk Management Plan (RMP) requirements, safety monitoring measures, and emergency fast-track approval pathways. Pharmaceutical companies should review these changes to maintain compliance, support uninterrupted imports, and ensure continued market access in Egypt.
Select Mandate HA
Select Mandate Function